Skip to main content

Mylan expands central nervous system portfolio with generic Exelon patch

Mylan has received the green light from the Food and Drug Administration for a generic version of Novartis’ Exelon Patch (rivastigmine transdermal system). The product is indicated for the treatment of dementia associated with mild, moderate and severe Alzheimer's disease and the treatment of mild-to-moderate dementia associated with Parkinson's disease.

The generic Exelon patch is available in 4.6 mg/24 hrs, 9.5 mg/24 hrs and 13.3 mg/24 hrs.

“The launch of generic Exelon Patch is another example of the investment Mylan is continuing to make into products that are difficult to develop and manufacture, particularly in transdermal drug delivery systems. The launch of this product also strengthens the company's growing central nervous system portfolio, which is a therapeutic area of continued focus for Mylan as we strive to provide better health for a better world,” said Mylan president Rajiv Malik.
This ad will auto-close in 10 seconds